In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Drug Hunter’s Assistant: Accelerating Drug Discovery With AI

The hype around Artificial Intelligence has been deafening in recent years, but real progress can only come when drug discovery culture and regulators catch up with the technology.

Digital Health Artificial Intelligence Outlook 2020

Global Health Systems Are Learning To Embrace AI As A Force For Good

The term artificial intelligence was coined at the Dartmouth Summer Research Project in 1956, but it is only in very recent years that it has been consistently at the top of the agenda in discussions on the future direction of health care. As a tool to improve both the quality and speed of care, AI is now increasingly seen as a realistic solution to the demand overload on clinicians. At the same time, techno-fears are abating. This confluence will transform health care radically in the next two decades.

Outlook 2020 Artificial Intelligence Medical Device

Coordinated Open Data Will Drive Next-Level Health Research

Experts from a European data sharing initiative talk to In Vivo about the importance of coordinated computational biology efforts for the future of life sciences innovation and the effective use of artificial intelligence.

Innovation Digital Health Business Strategies

UsernamePublicRestriction

Register